丙型肝炎病毒与肝细胞癌：发病机制及直接抗病毒药物的影响
Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals.
作者信息
Schietroma Ivan, Scheri Giuseppe Corano, Pinacchio Claudia, Statzu Maura, Petruzziello Arnolfo, Vullo Vincenzo
机构信息
Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy.
Department of Molecular Medicine, Laboratory of Virology, "Sapienza" University of Rome, Rome, Italy.
出版信息
Open Virol J. 2018 Feb 28;12:16-25. doi: 10.2174/1874357901812010016. eCollection 2018.
INTRODUCTION
Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually. Chronic infection can result in cirrhosis and hepatocellular carcinoma.
EXPLANATION
Epidemiological studies have indicated that persistent infection with hepatitis C virus (HCV) is a major risk for the development of hepatocellular carcinoma (HCC), mainly through chronic inflammation, cell deaths, and proliferation. Despite the new direct-acting antiviral drugs (DAA's) being able to clear the HCV, HCC recurrence rate in these patients is still observed.
CONCLUSION
In this review we highlighted some aspects that could be involved in the onset of HCV-induced HCC such as immune system, viral factors and host genetics factors.Moreover, we focused on some of the last reports about the effects of DAA's on the HCV clearance and their potential implications in HCC recurrence.
引言
全球范围内，有6400万至1.03亿人长期感染丙型肝炎病毒（HCV），美国有超过460万人感染，且每年有超过15000人死亡。慢性感染可导致肝硬化和肝细胞癌。
解释
流行病学研究表明，丙型肝炎病毒（HCV）持续感染是肝细胞癌（HCC）发生的主要风险因素，主要通过慢性炎症、细胞死亡和增殖起作用。尽管新型直接抗病毒药物（DAA）能够清除HCV，但这些患者中仍观察到HCC复发率。
结论
在本综述中，我们强调了一些可能与HCV诱导的HCC发病有关的方面，如免疫系统、病毒因素和宿主遗传因素。此外，我们关注了一些关于DAA对HCV清除的影响及其对HCC复发潜在影响的最新报道。
Zotero 插件